Pharmaceuticals

Argenx's stock plummets after a surprise failure in a late-stage study of its autoimmune disease drug, but the company is still preparing for a pivotal run with a $2.2B treatment.

7 sources 7 articles v 5 6d ago

◼ Archived Health 🔮 fades ✓

Cerevance rescues its Parkinson's drug with phase 3 win

7 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.

7 sources 7 articles v 5 6d ago

◼ Archived Business 🔮 fades ✓

High cost of GLP-1s drives some to seek cheaper, unregulated versions

15M Americans take GLP-1 drugs, with some seeking cheaper alternatives due to high costs.

7 sources 7 articles v 5 7d ago

◼ Archived Health 🔮 fades ✓

Some who take GLP-1s are suffering serious side effects, but it's unclear how often

Some who take GLP-1s are suffering serious side effects, but it's unclear how often.

7 sources 11 articles v 7 5d ago

◼ Archived Business 🔮 fades ✓

CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug

CSL’s $355 million upfront jump sits within a $1.6 billion partnership to co‑develop Alentis’s rare‑disease fibrosis drug.

6 sources 6 articles v 4 9d ago

◼ Archived Business 🔮 fades ✓

Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots

Vaxcyte's stock soars 36% as pneumococcal vaccine shows promise against Pfizer and Merck.

8 sources 8 articles v 6 9d ago

◼ Archived Business 🔮 fades ✓

America Wants to Make More Generic Drugs. India Shows Why That’s Hard.

US efforts to produce generic drugs domestically face challenges from India's pharmaceutical industry.

5 sources 5 articles v 3 12d ago

◼ Archived Business 🔮 fades ✓

Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D

Sanofi pays Regeneron $1B upfront for 4 early-stage assets to expand immunology alliance

8 sources 8 articles v 6 13d ago

◼ Archived Business 🔮 fades ✓

Merck licenses a KRAS G12D inhibitor for $400M upfront

Merck pays $400 million up front to lock worldwide rights to a KRAS G12D inhibitor in a deal that could swell to over $2 billion.

5 sources 6 articles v 3 16d ago

◼ Archived Health 🔮 fades ✓

New prescription warning for blood pressure, statins, iron medications

New safety alerts link common blood‑pressure, statin and iron pills to a surge in fall‑risk drug interactions among seniors.

6 sources 6 articles v 4 15d ago

◼ Archived Business 🔮 fades ✓

Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal

A $4 billion Merck‑Daiichi lung‑cancer partnership falters as the firms pull their FDA filing.

7 sources 7 articles v 5 16d ago

◼ Archived Business

GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug

4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

4 sources 4 articles v 2 17d ago

◼ Archived Business 🔮 fades ✓

Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology

5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

5 sources 5 articles v 3 19d ago

◼ Archived Business 🔮 fades ✓

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Novo Nordisk's shares dropped as Eli Lilly gains ground in GLP-1s

4 sources 5 articles v 3 19d ago

◼ Archived Business 🔮 fades ✓

Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease

Roche's Sefaxersen hits target in late-stage study for autoimmune disease

5 sources 5 articles v 3 22d ago

◼ Archived Health 🔮 fades ✓

Nearly 1 in 6 Kids on GLP-1s Developed This Problem Within a Year

Study finds link between GLP-1 drugs and nutritional deficiencies in children

8 sources 8 articles v 6 20d ago

◼ Archived Business 🔮 fades ✓

Novartis secures new radioligand in $900M deal as competition strengthens

Novartis’s $900 million BoomRay radioligand deal spotlights a China-origin, preclinical asset amid mounting competition in the biotech field

5 sources 5 articles v 14 22d ago

◼ Archived Business 🔮 fades ✓

Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

10 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

10 sources 10 articles v 8 21d ago

◼ Archived Business 🔮 fades ✓

Exclusive

20 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

35 sources 53 articles v 78 15d ago

◼ Archived Business 🔮 fades ✓

Novo defends diversification push as CEO eyes deals beyond obesity

4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

4 sources 6 articles v 3 22d ago

◼ Archived Business 🔮 fades ✓

Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

FDA's evaluation of Grail's cancer-detecting blood test sparks market optimism

10 sources 10 articles v 8 21d ago

◼ Archived Business 🔮 fades ✓

Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs

6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

6 sources 7 articles v 4 24d ago

◼ Archived Business 🔮 fades ✓

EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say

5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.

5 sources 5 articles v 3 26d ago

◼ Archived Business 🔮 fades ✓

Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

Novo Nordisk has signed an up to $1.4 billion licensing deal with Danish biotech Orbis Medicines to develop oral macrocycle drugs for cardiometabolic diseases.

6 sources 6 articles v 4 27d ago

◼ Archived Business 🔮 fades ✓

No more Nordisk as Novo goes it alone amid rebranding push

Novo Nordisk rebrands as Novo, marking a significant shift in the company's identity.

5 sources 6 articles v 3 29d ago

◼ Archived Business 🔮 fades ✓

FDA names acting heads of drug and vaccine centers to permanent roles

The FDA promotes its acting drug and vaccine chiefs to permanent posts, solidifying leadership for upcoming health initiatives.

5 sources 5 articles v 3 35d ago

◼ Archived Business 🔮 fades ✓

Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial

Bristol Myers' blood cancer cell therapy achieves key milestone in mid-stage trial

8 sources 8 articles v 6 35d ago

◼ Archived Business 🔮 fades ✓

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Roivant's experimental lung disease drug meets phase 2 goals

6 sources 7 articles v 4 36d ago

◼ Archived Business 🔮 fades ✓

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

AstraZeneca's COPD drug scores two late-stage trial wins, boosting hopes for a blockbuster treatment.

6 sources 6 articles v 4 36d ago

◼ Archived Business 🔮 fades ✓

Novartis cholesterol setback tests hopes for emerging heart disease drugs

Novartis' cholesterol drug fails critical cardiovascular test, casting doubt on multibillion-dollar heart disease drug race.

4 sources 6 articles v 3 37d ago

◼ Archived Business 🔮 fades ✓

Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline

Ultragenyx's stock has dropped 40% after a failed trial for its Angelman syndrome drug.

7 sources 7 articles v 5 41d ago

◼ Archived Business 🔮 fades ✓

Teva autoimmune antibody notches ph. 2 win in celiac disease

Teva's experimental antibody TEV-408 hits a key phase IIa endpoint in celiac disease studies.

9 sources 9 articles v 7 42d ago

◼ Archived Business 🔮 fades ✓

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Novartis secures a high-stakes subcutaneous delivery agreement with Alteogen, shifting industry dynamics and drawing varied market reactions.

9 sources 9 articles v 7 42d ago

◼ Archived Business 🔮 fades ✓

Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up

Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.

6 sources 6 articles v 4 43d ago

◼ Archived Business 🔮 fades ✓

Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Investors in Novo Nordisk are on edge as the pharmaceutical giant faces increasing competition in the GLP-1 market.

10 sources 10 articles v 8 43d ago

◼ Archived Business 🔮 holds ✗

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.

14 sources 14 articles v 13 42d ago

◼ Archived Business 🔮 fades ✓

Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns

Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.

8 sources 8 articles v 6 42d ago

◼ Archived Business 🔮 fades ✓

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

Nearly a dozen drug deals promise $600 billion in savings for American patients.

11 sources 13 articles v 54 44d ago

◼ Archived Health 🔮 fades ✓

Experts call for safer weight loss as concerns grow over GLP-1 use - News-Medical

11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.

11 sources 11 articles v 9 40d ago

◼ Archived Health 🔮 fades ✓

I lost the weight on a GLP-1

Men’s weight‑loss drugs face a double‑edge of stigma and rebound fears as GLP‑1 use spikes.

7 sources 8 articles v 5 45d ago

◼ Archived Business

Genentech doubles down on ADC-resistance via $1B DualityBio pact

Genentech's $1B bet on DualityBio's ADC technology signals a major shift in cancer treatment strategies.

5 sources 5 articles v 3 47d ago

◼ Archived Business 🔮 fades ✓

FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

The FDA has approved Gilead’s Bixlenvo, a once-daily pill designed to simplify HIV treatment for some patients.

7 sources 7 articles v 5 48d ago

◼ Archived Health 🔮 fades ✓

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify

Millions of Medicare patients with qualifying diagnoses are excluded from a new GLP-1 discount program.

6 sources 6 articles v 4 49d ago

◼ Archived Business 🔮 fades ✓

Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

A $1.5 billion China‑U.S. biotech pact puts American VCs and Haisco at the center of a new inflammatory‑disease platform.

8 sources 8 articles v 6 50d ago

◼ Archived Business 🔮 fades ✓

Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.

Eli Lilly's new weight-loss pill Foundayo is now available in the U.K., marking a significant milestone in the pharmaceutical industry.

9 sources 9 articles v 7 51d ago

◼ Archived Business 🔮 fades ✓

Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial

11 sources 13 articles v 14 55d ago

◼ Archived Health 🔮 fades ✓

Positional isomerisation of pyridine via nitrogen transposition

Scientists have found a way to move a single nitrogen atom to create new drug candidates, challenging conventional chemistry.

5 sources 5 articles v 3 57d ago

◼ Archived Business

Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals

Amylyx stock surged 55% after its GLP-1 blocker drug met all trial goals

4 sources 6 articles v 3 57d ago

◼ Archived Health 🔮 fades ✓

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.

9 sources 9 articles v 7 54d ago

◼ Archived Health 🔮 fades ✓

How to build an AI-driven digital organism

Scientists are racing to build AI-driven digital organisms to test drugs before human trials

5 sources 5 articles v 3 61d ago

◼ Archived Health 🔮 fades ✓

Researchers examine unanticipated benefits of GLP-1 medications

Researchers are finding new benefits of GLP-1 medications, shifting the conversation beyond weight loss.

7 sources 7 articles v 5 60d ago

◼ Archived Business

Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug

Eli Lilly is suing six companies to stop illegal sales of its unapproved weight loss drug, retatrutide.

4 sources 4 articles v 2 62d ago

◼ Archived Business 🔮 fades ✓

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

Eli Lilly is suing companies over the illegal sales of its experimental weight-loss drug, retatrutide.

11 sources 13 articles v 11 63d ago

What Archynetys tracks about Pharmaceuticals